In addition, TP53 mutation not only was involved in the de novo resistance in primary tumors but was also associated with poor survival in HR-positive and ERBB2-negative metastatic breast cancer.30 The alteration also correlated with the resistance to other endocrine agents such as palpociclib (r = −0.992; P < .001) and raloxifene hydrochloride (r = −0.994; P < .001) in a panel of breast cancer cell lines by data analysis using CellMiner, version 2.2 (https://discover.nci.nih.gov/cellminer/). Here, ERBB2 is linked to breast carcinoma.